Skip to main content
SpringerLink
Log in

Breast Disorders

  • Chapter
Women’s Health in Clinical Practice

Part of the book series: Current Clinical Practice ((CCP))

  • 984 Accesses

Abstract

Women in their 20s and 30s should undergo a clinical breast examination every 2 to 3 years. At the age of 40 years, the examination should be performed annually. It is recommended that women age 40 years and older should undergo mammography annually. There is no upper age limit for mammography. It should be continued annually as long as the woman remains in good health. Breast self-examination is also an option for women and, if done, should be performed monthly beginning in the 20s (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smith RA, Cokkinides V, Eyre HJ. American Caner Society Guidelines for the early detection of cancer. CA Cancer J Clin 2006;56:11–25.

    Article  PubMed  Google Scholar 

  2. U.S. Department of Health and Human Services. Quality determinants of mammography. Clinical practice guideline no. 13. U.S. Government Printing Office, Washington DC, 1994.

    Google Scholar 

  3. American College of Radiology. Breast imaging reporting and data system, 3rd ed. American College of Radiology, Reston, VA, 1998.

    Google Scholar 

  4. Sickles EA. Periodic mammographic follow-up of probably benign lesions, results of 3,184 consecutive cases. Radiology 1991;179:439–442.

    Google Scholar 

  5. Kopans DB. Breast Imaging. J.B. Lippencott Co., Philadelphia, pp 137–155.

    Google Scholar 

  6. Liberman L, Cohen MA, Dershaw DD, et al. Atypical ductal hyperplasia diagnosed at stereotactic core biopsy. AJR Am J Roentgenol 1995;164(5):1111–1113.

    CAS  PubMed  Google Scholar 

  7. Foster MC, Helvis MA, Gregory NE, et al. Lobular carcinoma in situ or atypical lobular neoplasia at core-needle biopsy: is excisional biopsy necessary? Radiology 2004;231:813–819.

    Article  PubMed  Google Scholar 

  8. Berg WA, Mrose HE, Ioffe OB. Atypical lobular hyperplasia or lobular carcinoma in situ at core-needle breast biopsy. Radiology 2001;218:503–509.

    CAS  PubMed  Google Scholar 

  9. Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologie-pathologie correlation. Am J Roentgenol 2001;176:1255–1259.

    CAS  Google Scholar 

  10. Morris KT, Vetto JT, Petty JK. A new score for the evaluation of palpable breast masses in women under 40. Am J Surg 2002;184:346–347.

    Article  PubMed  Google Scholar 

  11. Vetto J, Pommier R, Schidt W, et al. Use of the triple test for palpable breast lesions yields high diagnostic accuracy and cost savings. Am J Surg 1995; 169:519–522.

    Article  CAS  PubMed  Google Scholar 

  12. Mansel RE, Wisby JR, Hughes LE. Controlles trial of the antigonadotropin danazol in painful nodular benign breast disease. Lancet 1982;1:928–933.

    Article  CAS  PubMed  Google Scholar 

  13. Mansel RE, Dogliotti L. European multicentre trial of bromocriptine in cyclical mastalgia. Lancet 1990;335:190–195.

    Article  CAS  PubMed  Google Scholar 

  14. Kontosolis E, Stefanidis K, Navrozoglou I, et al. Comparison of tamoxifen with danazol in the treatment of cyclical mastalgia. Gynecol Endocrol 1997;11:393–398.

    Article  Google Scholar 

  15. Jardines L. Management of nipple discharge. The American Surgeon 1996;62:119–122.

    CAS  PubMed  Google Scholar 

  16. Carter BA, Page DL, Schuyler, et al. No elevation in the long term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasic. Cancer 2001;92:30–36.

    Article  CAS  PubMed  Google Scholar 

  17. Diaz NM, Palmer JO, McDivitt RW. Carcinoma arising within fibroadenomas of the breast: a clinicopathologic study of 105 patients. Am J Pathol 1991;95:614–620.

    CAS  Google Scholar 

  18. Reinfrus M, Mitus J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer 1996;77:910–916.

    Article  Google Scholar 

  19. Zurrida S, Bartoli C, Galimberti V, et al. which therapy for unexpected phyllodes tumour of the breast? Eur J Cancer 1992;28:673–675.

    Article  Google Scholar 

  20. Rubin E, Visscher DW, Alexander RW, et al. Proliferative disease and atypia in biopsies performed for non-palpable lesions detected mammographically. Cancer 1988;61:2077–2082.

    Article  CAS  PubMed  Google Scholar 

  21. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–151.

    CAS  PubMed  Google Scholar 

  22. Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;43:737–769.

    Article  Google Scholar 

  23. Page DL, Kidd TJ, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232–1239.

    Article  CAS  PubMed  Google Scholar 

  24. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer 1985;55:2698–2708.

    Article  CAS  PubMed  Google Scholar 

  25. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 And BRCA2 mutations. N Engl J Med 2002;346:1616–1622.

    Article  PubMed  Google Scholar 

  26. Kauff ND, Satagopan JM, Robson ME, et al. Risk reducing salping-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–1615.

    Article  PubMed  Google Scholar 

  27. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77–84.

    Article  CAS  PubMed  Google Scholar 

  28. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879–1886.

    Article  CAS  PubMed  Google Scholar 

  29. Fisher B, Constatino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project. P-1 study. J Natl Cancer Institute 1998;90:1371–1388.

    Article  CAS  Google Scholar 

  30. Benson EA. Management of breast abscesses. World J Surg 1989;13:753–760.

    Article  CAS  PubMed  Google Scholar 

  31. Schafer P, Furrer C, Mermillod B. An association of cigarette smoking with recurrent subareolar abscess. Int J Epidemiol 1988;17:810–817.

    Article  CAS  PubMed  Google Scholar 

  32. Walker AP. A prospective study of the microflora of nonpuerperal breast abscesses. Arch Surg 1988;123:908–915.

    CAS  PubMed  Google Scholar 

  33. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin 2006;56:37–47.

    Article  PubMed  Google Scholar 

  34. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004:350:1430–1441.

    Article  CAS  PubMed  Google Scholar 

  35. Page D, Dupont W, Rogers L, et al. Intraductal carcinoma of the breast; follow-up after biopsy only. Cancer 1982:49:751–760.

    Article  CAS  PubMed  Google Scholar 

  36. Silverstein MJ. The Van Nuys prognostic index for ductal carcinoma in situ. Breast J 1996: 2:38–48.

    Article  Google Scholar 

  37. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441–452.

    CAS  PubMed  Google Scholar 

  38. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993–2000.

    Article  CAS  PubMed  Google Scholar 

  39. Fisher ER, Anderson S, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project protocol B-06: 10-year pathologic and clinical prognostic discriminants. Cancer 1993;71:2507–2514.

    Article  CAS  PubMed  Google Scholar 

  40. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998;52:227–237.

    Article  CAS  PubMed  Google Scholar 

  41. Contessa G, Mourisse H, Friedman S, et al. The importance of histologic grade in longterm prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustav-Roussy. J Clin Oncol 1987;5:1378–1386.

    Google Scholar 

  42. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with Stage I or II breast cancer. J Clin Oncol 1994; 12:888–894.

    CAS  PubMed  Google Scholar 

  43. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005;97:439–448.

    PubMed  Google Scholar 

  44. Van de Vijar MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer. N Engl J Med 1988;319:1239–1245.

    Article  Google Scholar 

  45. Wistansley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erb-2 in primary breast cancer. Br J Cancer 1991;63:447–450.

    Google Scholar 

  46. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.

    Article  CAS  PubMed  Google Scholar 

  47. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.

    Article  CAS  PubMed  Google Scholar 

  48. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659–1672.

    Article  CAS  PubMed  Google Scholar 

  49. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of breast cancer. N Engl J Med 2002;347:1233–1243.

    Article  PubMed  Google Scholar 

  50. Gage I, Recht A, Gelman R, et al. Long-term outcome following breast conserving surgery and radiation therapy. Int J Radiati Oncol Biol Phys 1995;33:245–254.

    Article  CAS  Google Scholar 

  51. Nixon AJ, Neuberg D, Hayes EF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with Stage I or II breast cancer. J Clin Oncol 1994;12:888–895.

    CAS  PubMed  Google Scholar 

  52. Pierce LJ, Strawderman M, Narod SA. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360–3369.

    CAS  PubMed  Google Scholar 

  53. Smitt MC, Nowels JW, Zdeblich MJ, et al. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 1995;76:259–269.

    Article  CAS  PubMed  Google Scholar 

  54. Freedman G, Fowble B, Hanlon A, et al. Patients with early stage invasive cancer with close or positive surgical margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiati Oncol Biol Phys 1999;44:1005–1114.

    Article  CAS  Google Scholar 

  55. Obedian E, Haffty BG. Negative margin status improves local control in conservatively managed breast cancer patients. Cancer J 1999;6:28–37.

    Google Scholar 

  56. Pittinger TP, Maronian NC, Poulter CA, et al. Importance of margin status in outcome of breast-conserving surgery for carcinoma. Surgery 1994; 11:605–612.

    Google Scholar 

  57. Singletary SE, McNesse M. Segmental mastectomy and irradiation in the treatment of breast cancer. Am J Clin Oncol 1988;11:679–689.

    Article  CAS  PubMed  Google Scholar 

  58. Shivers S, Cox C, Leight G, et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 2002;9:248–255.

    Article  PubMed  Google Scholar 

  59. Rahusen FD, Torrenga H, van Diest PJ, et al. Predictive factors for metastatic involvement of nonsentinel nodes in breast cancer. Arch Surg 2001;136:1059–1063.

    Article  CAS  PubMed  Google Scholar 

  60. Kamath VJ, Giuliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla. Arch Surg 2001;136:688–693.

    Article  CAS  PubMed  Google Scholar 

  61. Loza J, Colo F, Nadal J, et al. Axillary recurrence after sentinel node biopsy for operable breast cancer. Eur J Surg Oncol 2002;28:897–898.

    Article  CAS  PubMed  Google Scholar 

  62. Mamounas E, Brown A, Smith R, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: updated results form NSABP B-27. Proc Soc Clin Oncol 2002;21:36a.

    Google Scholar 

  63. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from the National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monograph 2001; p. 96.

    Google Scholar 

  64. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel (taxotere) to preoperative doxorubicin and cyclophosphamide (AC): Preliminary results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27. J Clin Oncol 2003;21:4165–4174.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Albert Einstein Medical Center, Philadelphia, PA

    Lori Jardines MD

Authors
  1. Lori Jardines MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Family Medicine Residency Program, Abington Memorial Hospital, Abington, PA

    Amy L. Clouse MD

  2. Department of Medicine, Drexel University College of Medicine, Philadelphia, PA

    Katherine Sherif MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Jardines, L. (2008). Breast Disorders. In: Clouse, A.L., Sherif, K. (eds) Women’s Health in Clinical Practice. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-469-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-469-8_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-631-3

  • Online ISBN: 978-1-59745-469-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation